Summary of Study ST000464
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000356. The data can be accessed directly via it's Project DOI: 10.21228/M81K5Z This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000464 |
| Study Title | Transpulmonary metabolomics in pulmonary arterial hypertension |
| Study Summary | We hypothesize that transpulmonary metabolomic profiling will demonstrate a PAH-specific metabolic signature. We will examine organ-specific metabolism by measuring blood flowing into (pulmonary artery) and out of (pulmonary artery wedge) the pulmonary circulation at the time of right heart catheterization (RHC). We will compare PAH to patients without PH and to a disease control cohort with PH due to left heart disease (pulmonary ventrical hypertension - PVH). |
| Institute | University of North Carolina |
| Laboratory | Sumner Lab |
| Last Name | Sumner |
| First Name | Susan |
| Address | Eastern Regional Comprehensive Metabolomics Resource Core, UNC Nutrition Research Institute, 500 Laureate Way, Kannapolis, NC, 28081 |
| susan_sumner @unc.edu | |
| Phone | 704-250-5066 |
| Submit Date | 2016-09-07 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | 1r |
| Analysis Type Detail | NMR |
| Release Date | 2018-10-10 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000356 |
| Project DOI: | doi: 10.21228/M81K5Z |
| Project Title: | Transpulmonary metabolomics in pulmonary arterial hypertension |
| Project Summary: | Pulmonary arterial hypertension (PAH) is a progressive and incurable disease characterized by obliteration of the pulmonary arterioles, elevated pulmonary vascular resistance (PVR), and eventual right heart failure and death. Current medical therapy for PAH is aimed at reducing PVR by targeting pathways involved in vasodilation. Pulmonary vasodilators improve functional capacity but do not target the underlying vascular obstruction. Despite multiple approved therapies, median survival after diagnosis is less than five years, indicating that additional therapeutic targets are needed. |
| Institute: | Vanderbilt University |
| Last Name: | Brittain |
| First Name: | Evan |
| Address: | 2525 West End Ave, Suite 300, Nashville TN 37203 |
| Email: | evan.brittain@Vanderbilt.Edu |
| Phone: | (615) 322-2318 |
